Pages that link to "Q35132029"
Jump to navigation
Jump to search
The following pages link to A novel tetravalent bispecific TandAb (CD30/CD16A) efficiently recruits NK cells for the lysis of CD30+ tumor cells (Q35132029):
Displaying 38 items.
- Blinatumomab: a bispecific T cell engager (BiTE) antibody against CD19/CD3 for refractory acute lymphoid leukemia (Q26785828) (← links)
- Immunocytokines and bispecific antibodies: two complementary strategies for the selective activation of immune cells at the tumor site (Q28066935) (← links)
- Second- and third-generation ALK inhibitors for non-small cell lung cancer (Q28072496) (← links)
- Second-generation inhibitors of Bruton tyrosine kinase (Q28076118) (← links)
- Improving natural killer cell cancer immunotherapy (Q28087719) (← links)
- A FcγRIII-engaging bispecific antibody expands the range of HER2-expressing breast tumors eligible to antibody therapy. (Q34221898) (← links)
- Bispecific Antibodies as a Development Platform for New Concepts and Treatment Strategies (Q34548319) (← links)
- Fc Engineering for Developing Therapeutic Bispecific Antibodies and Novel Scaffolds (Q34550963) (← links)
- A Novel Bispecific Antibody against Human CD3 and Ephrin Receptor A10 for Breast Cancer Therapy (Q35871726) (← links)
- A phase 1 study of the bispecific anti-CD30/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphoma (Q35925674) (← links)
- Complete remission after single agent blinatumomab in a patient with pre-B acute lymphoid leukemia relapsed and refractory to three prior regimens: hyperCVAD, high dose cytarabine mitoxantrone and CLAG. (Q37129564) (← links)
- AFM13: a first-in-class tetravalent bispecific anti-CD30/CD16A antibody for NK cell-mediated immunotherapy (Q38558611) (← links)
- ABT-199 (venetoclax) and BCL-2 inhibitors in clinical development (Q38640917) (← links)
- NK cells and cancer: you can teach innate cells new tricks. (Q38676458) (← links)
- "NextGen" Biologics: Bispecific Antibodies and Emerging Clinical Results (Q38723957) (← links)
- Harnessing NK Cell Memory for Cancer Immunotherapy (Q38988913) (← links)
- Bruton tyrosine kinase inhibitor ONO/GS-4059: from bench to bedside (Q38989496) (← links)
- Acute myeloid leukemia targets for bispecific antibodies (Q39117761) (← links)
- The making of bispecific antibodies (Q42323236) (← links)
- Detection of a phosphorylated glycine-serine linker in an IgG-based fusion protein. (Q42330118) (← links)
- A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19(+) tumor cells (Q42601428) (← links)
- Recombinant Antibodies to Arm Cytotoxic Lymphocytes in Cancer Immunotherapy (Q42660142) (← links)
- Next generation antibody drugs: pursuit of the 'high-hanging fruit'. (Q46527001) (← links)
- Bispecific antibodies in cancer immunotherapy (Q51309023) (← links)
- Development of a bispecific antibody tetramerized through hetero-associating peptides (Q51784482) (← links)
- Acquired Natural Killer Cell Dysfunction in the Tumor Microenvironment of Classic Hodgkin Lymphoma. (Q52680552) (← links)
- Tumor immunotherapy: New aspects of natural killer cells. (Q55107050) (← links)
- Bispecific antibodies in cancer immunotherapy (Q56893015) (← links)
- Bispecific T-cell engagers: towards understanding variables influencing the in vitro potency and tumor selectivity and their modulation to enhance their efficacy and safety (Q58617435) (← links)
- Single-Chain Variable Fragment-Based Bispecific Antibodies: Hitting Two Targets with One Sophisticated Arrow (Q64058873) (← links)
- Immunoglobulin Gamma-Like Therapeutic Bispecific Antibody Formats for Tumor Therapy (Q64227267) (← links)
- Amgen's bispecific antibody puffs across finish line (Q86884183) (← links)
- Design and Production of Bispecific Antibodies (Q90212096) (← links)
- Identification of anti-CD16a single domain antibodies and their application in bispecific antibodies (Q90350008) (← links)
- Redirected optimized cell killing (ROCK®): A highly versatile multispecific fit-for-purpose antibody platform for engaging innate immunity (Q92579895) (← links)
- Antibody-Directed Therapies: Toward a Durable and Tolerable Treatment Platform for CTCL (Q92652614) (← links)
- A Natural Impact: NK Cells at the Intersection of Cancer and HIV Disease (Q93047632) (← links)
- Bispecific, T-Cell-Recruiting Antibodies in B-Cell Malignancies (Q95840982) (← links)